Most cervical carcinomas express the E6 and E7 proteins of a high-risk human papillomavirus (HPV). These proteins affect growth control by interfering with the functions of cell regulatory proteins, promoting oncogenic transformation. A key target of E7 is the tumor suppressor protein pRb, which directly interacts with E7. However, binding to additional cellular regulatory proteins is clearly required for oncogenesis, as mutants of E7 have been identified that bind to pRb, yet fail to transform efficiently. Here we demonstrate the interaction of the HPV 6, 16 and 18 E7 proteins with the pCAF acetyltransferase, which has been reported to function as a coactivator for a variety of transcription factors including p53. Mutation of a highly conserved leucine residue within the zinc finger region of HPV 16 E7 disrupts binding to pCAF and also impairs transformation and transcriptional activation. HPV 16 E7 interacts with the acetyltransferase domain of pCAF, and reduces its acetyltransferase activity in vitro. Our analysis of the interaction between the pCAF acetyltransferase and E7 provides new insight into the mechanisms by which the E7 oncoproteins can alter cellular gene expression and growth.
Introduction
Papillomaviruses are small DNA viruses that induce epithelial hyperplasias (zur Hausen and de Villiers, 1994) . Over 77 different human papillomavirus (HPV) types have been identified. These can be subdivided into two groups: the low-risk types which are associated with benign warts, and the high-risk types which induce squamous epithelial hyperplasias that may progress to malignancy. Infection with high-risk HPVs is strongly associated with the etiology of cervical carcinoma and a number of other human cancers (zur Hausen and de Villiers, 1994) .
The high-risk HPVs express two major transforming oncogenes, E6 and E7, both of which are consistently expressed in cervical cancers (Vousden, 1993; zur Hausen, 1996) . The HPV E7 gene encodes an acidic phosphoprotein of, typically, 98 amino-acid residues (Vousden, 1993) . Expression of high-risk HPV E7 is sufficient to transform primary rodent cells in cooperation with activated ras (Phelps et al., 1988) , immortalize human keratinocytes (Halbert et al., 1991; Jewers et al., 1992) and induce epithelial tumors in transgenic mice (Herber et al., 1996; Gulliver et al., 1997) . The E7 oncoprotein is thought to function principally by binding to the pRb tumour suppressor protein and related family members p107 and p130 (Dyson et al., , 1992 Munger et al., 1989) . This interaction releases transcription factors of the E2F family, driving the host cell into the S phase of the cell division cycle (Banks et al., 1990; Chellappan et al., 1992; Morris et al., 1993) . The interaction of E7 with pRb maps to the pocket protein-binding motif LXCXE located at residues 22-26 in the high-risk HPV 16 E7 protein . Although an intact pRb-binding domain is necessary for transformation of primary cells, this interaction alone is not sufficient for the transformation as E7 mutants have been constructed that bind to pRb, yet fail to transform (Banks et al., 1990) . This indicates that E7 must interact with additional cellular proteins to carry out its functions.
Here, we demonstrate the interaction of HPV E7 proteins with the pCAF acetyltransferase. pCAF has been reported to function as a transcriptional coactivator for a variety of transcription factors (Blanco et al., 1998; Sakaguchi et al., 1998; Jiang et al., 1999; Itoh et al., 2000; Polesskaya et al., 2000; Spilianakis et al., 2000) , and has been shown to be involved in diverse processes such as muscle development (Polesskaya et al., 2000) and response to DNA damage (Sakaguchi et al., 1998) . Mutational analysis indicates that a residue within the zinc finger region of E7 critical to the protein's transformation and transcriptional activation functions is involved in binding pCAF. Our investigation of the interaction between the pCAF acetyltransferase and E7 provides new insight into the mechanisms by which the E7 oncoproteins can alter cellular gene expression and growth.
Results

HPV 16 E7 inhibits yeast growth in a Gcn5p-dependent fashion
The HPV 16 E7 protein can function in yeast as a transcriptional activation domain when fused to a DNA-binding domain (DBD), suggesting that it can interact with components of the transcriptional apparatus Luscher-Firzlaff et al., 1999) . Yeast colonies transformed with a vector expressing E7 as a fusion to the yeast Gal4p DBD displayed reduced growth with respect to their counterparts transformed with a control plasmid expressing only the Gal4p DBD (Figure 1, top row) . Expression of the HSV VP16 transcriptional activation domain fused to the Gal4p DBD similarly inhibited growth. Growth inhibition in yeast by transcriptional activation domains such as HSV VP16 has been reported previously and is postulated to occur via sequestration of transcriptional machinery, which limits its availability for essential cell functions (Berger et al., 1992) . In support of this concept, growth inhibition by HSV VP16 can be overcome by mutation of Gcn5p, a component of the ADA transcriptional coactivator complex (Marcus et al., 1994) . Like HSV VP16, E7 was unable to inhibit growth in the FY1370 yeast strain lacking a functional GCN5 gene (Figure 1 , bottom row), whereas both VP16 and E7 inhibited growth in the isogenic wild-type FY86 strain (Figure 1 , middle row). These results suggest that E7 inhibits growth in yeast by targeting the Gcn5p component of the ADA complex.
Expression of pCAF relieves HPV 16 E7-mediated inhibition of yeast growth
Based on the assumption that growth inhibition by E7 results from an interaction between E7 and Gcn5p, we next tested whether expression of pCAF, a mammalian homologue of Gcn5p (Yang et al., 1996) , would restore growth to yeast by binding and sequestering E7. We cotransformed yeast with a vector expressing E7 and vectors expressing either the amino portion or carboxyl portion of pCAF (pCAF or pCAF , respectively). Expression of pCAF 310-832 restored rapid growth to yeast expressing E7, whereas yeast expressing E7 and pCAF continued to grow slowly (Figure 2 ).
pCAF and HPV 16 E7 interact in a yeast two-hybrid assay
Our observation that expression of pCAF 310-832 suppressed E7-mediated growth inhibition suggested that there may be a physical interaction between these two proteins. We tested this directly using the yeast twohybrid test. Fragments of the pCAF protein (Figure 3 , left) were expressed as fusions to the LexA DBD, and assayed for their ability to interact with wild-type HPV16 E7 expressed as a fusion with the B42 transcriptional activation domain. E7 interacted strongly with pCAF , but not with pCAF ( Figure 3 , right). The interaction between E7 and pCAF diminished with progressive truncation of pCAF, and was completely abrogated by deleting the 218 carboxy terminal amino-acid residues. No interaction was detected between E7 and pCAF , suggesting that the minimal region of interaction with E7 maps between amino-acid residues 310-654, which roughly corresponds to the HAT domain ( Figure 3) .
We next determined which region of HPV 16 E7 was important for interaction with pCAF. Yeast cells were cotransformed with pCAF , which had shown the strongest interaction with E7 WT , and a series of E7 mutants (Figure 4 ). The region of interaction with pCAF appeared to be contained within the carboxyl portion of E7, since residues 1-57 of E7 did not interact with pCAF, while residues 39-98 interacted strongly (Figure 4b ). We also tested a panel of E7 mutants with small deletions or point mutations for interaction with pCAF . In a parallel series of experiments, these same mutants were tested for interaction with pRb, which is known to interact with the LXCXE motif located in the amino-terminal portion of E7 . Only mutants with a threefold or greater ratio of their ability to interact with pCAF with respect to pRb were considered impaired for interaction, and these are indicated in black ( Figure 4c ). This approach was necessary to compensate for the effects of the mutations on E7 stability, as Western blot analysis indicated that many of the mutants were expressed at levels below E7 WT (Figure 4d ). Using this criterion, the only mutant specifically impaired for interaction with pRb was E7 DDLYC , which deletes the known pRb interaction domain of E7. Similarly, only the E7 L67R mutation, located within the zinc finger, displayed a specific reduction in its ability to bind pCAF.
E7 proteins from both high-and low-risk HPV types bind pCAF
A sequence comparison of E7 proteins from different HPV types indicated that the leucine residue at aminoacid 67 of HPV 16 E7 is invariant among all 42 members of HPV supergroup A (data not shown), suggesting that pCAF may be a common target of each of these viral proteins. We tested the ability of the high-risk HPV 18 and low-risk HPV 6 E7 proteins to bind pCAF in the yeast two-hybrid test. Both HPV 18 and 6 E7 proteins interacted with pCAF in our experiments as well as or better than HPV 16 E7, suggesting that pCAF is a common target of both high-and low-risk HPV E7 proteins (data not shown).
HPV 16 E7 reduces acetyltransferase activity of pCAF in vitro
Next, we examined the consequences of this interaction on the acetyltransferase activity of pCAF. Recombinant maltose-binding protein (MBP)-pCAF protein was purified from E. coli and used in an in vitro histone acetyltransferase (HAT) assay alone or with addition of recombinant GST-E7 WT or GST-E7 L67R ( Figure 5 ). E7 WT reduced pCAF's ability to acetylate free histones, although to a lesser extent than adenovirus type 5 E1A 13S (Figure 5a ), which has been previously reported to inhibit pCAF's HAT activity (Hamamori et al., 1999) . We also compared the effect of E7 WT to E7 L67R on acetyltransferase activity ( Figure 5b ). E7 WT inhibited pCAF activity in a dose-dependent manner, whereas the E7 L67R mutant had no effect regardless of the amount of protein used.
HPV 16 E7 and pCAF interact in mammalian cells
We also determined whether E7 and pCAF can interact in mammalian cells. COS-1 cells were cotransfected with vectors expressing glutathione S-transferase (GST)-E7 and hemagglutinin (HA)-tagged pCAF. The GST-E7 fusion protein was precipitated from cell extracts with glutathione-sepharose beads, which were then used in a HAT activity assay ( Figure 6a ). No significant increase in HAT activity was detected in precipitates from cells transfected with either GST-E7 or HA-tagged pCAF alone. However, 3.5-fold more HAT activity coprecipitated with E7 from cells cotransfected with E7 WT and HA-tagged pCAF. Protein coprecipitating with the glutathione-sepharose beads was also analysed by Western blotting with an anti-HA antibody ( Figure 6b ). We detected HA-tagged pCAF in precipitates with GST-E7 only in cells transfected with expression vectors for E7 WT and pCAF. In contrast to what was observed in the yeast two-hybrid analysis (Figure 4c ), the E7 L67R mutant retained the ability to interact with pCAF in mammalian cells ( Figure 6b ).
Nevertheless, these results demonstrate that E7 can associate with pCAF in mammalian cells, and suggest that it may interact with pCAF via several independent mechanisms.
HPV 16 E7 L67R is impaired for transactivation
To determine if the inability of E7 to interact with pCAF via the zinc finger had any functional consequences, we examined the ability of Gal4p DBD-E7 WT and Gal4p DBD-E7 L67R to activate transcription from a Gal4p-responsive luciferase reporter gene when transiently transfected into CV-1 cells (Table 1 ). The E7 L67R mutant, which does not bind pCAF in the yeast HPV E7 proteins interact with the pCAF N Avvakumov et al two-hybrid tests or inhibit pCAF HAT activity in vitro, was significantly impaired for the activation of transcription as compared to E7 WT or the E7 DDLYC and E7 S71I mutants, which bind pCAF.
Discussion
The interaction between the HPV E7 proteins and members of the pRb tumour suppressor protein family induces the host cell to re-enter the cell cycle (Banks et al., 1990; Chellappan et al., 1992; Morris et al., 1993) . However, these interactions alone do not account for all the functions that the E7 oncoprotein performs in infected cells. Importantly, regions both amino terminal and carboxyl terminal to the pRb-binding region are essential for transformation by E7 (Banks et al., 1990) , suggesting that these regions interact with other key components of the cell regulatory apparatus.
Here we show that the HPV 16 E7 protein interacts with the pCAF acetyltransferase. This was confirmed via yeast two-hybrid analyses (Figures 3 and 4) , yeast growth restoration analysis (Figure 2 ) and coprecipitation from mammalian cells ( Figure 6 ). In addition, the E7 proteins of HPV 6 and 18 also interacted with pCAF (data not shown). The carboxyl-terminal zinc finger portion of HPV 16 E7 was sufficient for binding ( Figure 4b ), which was also dependent on the presence of an intact HAT domain within pCAF (Figure 3 ).
While this manuscript was in preparation, full-length wild-type E7 was independently shown to interact with pCAF in vitro and in vivo, corroborating our observations (Huang and McCance, 2002) . In this report, we present a more detailed analysis of this interaction and its consequences. Using yeast two-hybrid analysis, we tested a panel of HPV 16 E7 mutants in order to identify the critical residues involved in the interaction with pCAF ( Figure 4c ). Only the zinc finger mutant E7 L67R was specifically impaired for binding to pCAF in this assay. Importantly, this leucine residue is invariant among the E7 proteins of all 42 members of HPV supergroup A, suggesting that pCAF may be a common target. This is supported by our observation that the E7 proteins of HPV 6 and 18 could also interact with pCAF (data not shown). Intriguingly, the E7 L67R mutant retained binding to pCAF in COS-1 cells (Figure 6b ). One potential explanation for this difference might be that E7 indirectly interacts with pCAF in mammalian cells via a cellular target not present in yeast. Alternatively, post-translational modifications unique to mammalian cells may regulate an independent, and not necessarily equivalent, interaction with pCAF.
Clearly, our evidence supports a critical role for the interaction of E7 with pCAF via the leucine residue at position 67. Specifically, the E7 L67R mutant has no effect on the ability of pCAF to acetylate histones in vitro, whereas wild-type HPV 16 E7 substantially inhibits this activity ( Figure 5 ). Furthermore, we show that HPV 16 E7 can function as a transcriptional activator in mammalian cells when fused to a DBD and that the leucine at residue 67 is essential for this function (Table 1) . In contrast to E7 L67R , the E7 S71I and E7 DDLYC mutants, which retain binding to pCAF in yeast two-hybrid tests, exhibit wild-type ability to activate transcription (Table 1 ). This result suggests that the interaction of the HPV 16 E7 zinc finger with pCAF is required for transcriptional activation by E7. Yeast two-hybrid analysis of the interaction of the amino or carboxyl portions of HPV 16 E7 with pCAF. Yeast strain EGY48 was transformed with vectors expressing residues 310-832 of human pCAF fused to the LexA DBD and vectors expressing either amino acids 1-57 or 39-98 of E7 fused to a transcriptional activation domain. b-galactosidase assays were performed as described in the Materials and methods. (c) Yeast two-hybrid analysis of the interaction of HPV 16 E7 mutants with pCAF and pRb. Yeast strain EGY48 was transformed with vectors expressing residues 310-832 of human pCAF or pRb fused to the LexA DBD and vectors expressing the E7 mutants described in (a) fused to a transcriptional activation domain. Only those mutants whose interaction with one target protein was reduced by at least threefold with respect to the other target protein were considered to be significantly impaired for binding, and these are indicated as black bars. (d) Western blot of expression levels of the HPV 16 E7 wild-type and mutant proteins. Yeast strain EGY48 was transformed with vectors expressing wild-type or mutant E7 proteins. Cell extracts were analysed by Western blotting using the 3F10 anti-HA antibody HPV E7 proteins interact with the pCAF N Avvakumov et al
In addition to the pRb family of proteins, E7 has been shown to interact with the S4-ATPase component of the 26S proteasome (Berezutskaya and Bagchi, 1997) , and cyclin-dependent kinase inhibitors (Zerfass- Thome et al., 1996; Jones et al., 1997) . These interactions appear to be focused on deregulation of the cell cycle and degradation of cell cycle checkpoint regulators. On the other hand, the interactions between E7 and TATA-binding protein (TBP) , the Mi2b component of a histone deacetylase complex (Brehm et al., 1999a) , the MPP2 fork head domain transcription factor (Luscher-Firzlaff et al., 1999) , the Oct-4 POU domain transcription factor (Brehm et al., 1999b) , the IRF-1 transcription factor (Park et al., 2000) and now with the pCAF acetyltransferase, strongly suggest a potential role for E7 as a transcriptional regulator. The interactions with TBP, Mi2b and pCAF take place within the zinc finger domain of E7, and the leucine residue at position 67 is required for binding to both Mi2b (Brehm et al., 1999a) and pCAF (Figure 4c ). This raises the possibility that the zinc finger region of E7 mimics the interaction domain of an endogenous cellular protein that can also bind both pCAF and Mi2b. Interestingly, the S71I mutation, which is adjacent to L67R, differs in that it has little effect on interaction with pCAF ( Figure 4c ) or Mi2b (Brehm et al., 1999a) , suggesting that these two unrelated proteins recognize overlapping or identical portions of E7. Additional mutational analysis will be required to define these interaction surfaces in detail.
How does binding to Mi2b or pCAF contribute to E7 function? Mi2b is a component of the nucleosome remodeling and histone deacetylation (NURD) complex, which contains approximately 18 polypeptides and exhibits ATP-dependent chromatin remodeling and histone deacetylase activity (Xue et al., 1998) . Therefore, the recruitment of the NURD complex by E7 was originally suggested to be involved in the transcriptional repression of target genes by E7 (Brehm et al., 1999a) . Recent evidence has demonstrated that E7 likely recruits (a) MPB-pCAF 310-832 was mixed with a 10-fold excess of GST-E7 WT , -E7 L67R or -E1A 13S , and HAT activity of the mixture was evaluated as described in Materials and methods. HAT activity measured in the MBP/GST sample was normalized to one. (b) MPB-PCAF 310-832 was mixed with GST-E7 WT or GST-E7 L67R in proportions indicated and HAT activity of the mixture was evaluated as described in Materials and methods. HAT activity measured with MBP-pCAF in the absence of GST-E7 was normalized to 100% and GST-E7. HAT activity coprecipitating with glutathionesepharose beads from cell extracts was determined as described in the Materials and methods. HAT activity present in precipitations from cells transfected with empty vectors was normalized to one. (b) Western blot analysis of glutathione-sepharose precipitates. Precipitates prepared as described above or unprecipitated whole cell extracts (WCE, 10% of extract used for precipitations) were resolved by SDS-PAGE, and Western blot analysis was performed. The 3F10 antihemagglutinin (a-HA) antibody was used to detect HA-tagged pCAF, while the antiglutathione-Stransferase (a-GST) antibody was used to detect GST-tagged E7 the NURD complex to promoters containing binding sites for the IRF-1 transcription factor by interacting directly with IRF-1 and Mi2b. This leads to an E7-mediated inhibition of IRF-1-dependent transcription, which may be involved in suppressing a cellular immune response to viral infection (Park et al., 2000) .
pCAF is a component of a complex of more than 20 polypeptides in human cervical cells, a normal target of HPV infection (Ogryzko et al., 1998) . The composition of the pCAF complex is similar to that of the yeast SAGA transcriptional adaptor complex in that it contains human orthologues of yeast ADA and SPT proteins as well as TBP-associated factors (TAFs) (Schiltz and Nakatani, 2000) . In contrast to the NURD complex that deacetylates histones, the pCAF complex possesses acetyltransferase activity. Histone acetylation is generally linked to relaxation of the local chromatin structure, which leads to improved accessibility of DNA by components of the transcriptional apparatus (Kuo and Allis, 1998) . Our current state of knowledge makes it difficult to reconcile E7's abilities to bind components of both an acetyltransferase and a deacetylase complex. However, it is possible that such interactions are regulated by post-translational modifications of E7 within the host cell. Alternatively, E7 may preferentially bind the pCAF or the NURD complex in the context of a particular promoter to which it initially becomes tethered via an interaction with a promoter-specific factor.
As to the reasons for why E7 targets Mi2b and pCAF, one potential explanation is that it does so simply to disrupt normal functions of the respective complexes. Given what is currently known about the activities of the pCAF complex, this is not an implausible hypothesis. In addition to acetylating histones, the pCAF complex also acetylates a variety of other cellular proteins, and augments the activities of cellular transcription factors including p53 (Sakaguchi et al., 1998; Liu et al., 1999) , MyoD (Polesskaya et al., 2000) , Notch (Kurooka and Honjo, 2000) , nuclear hormone receptors (Blanco et al., 1998) , the SMAD proteins (Itoh et al., 2000) and NF-kB (Sheppard et al., 1999) . As these target proteins regulate a variety of activities such as proliferation, differentiation, apoptosis and DNA damage repair, pCAF represents an attractive target for a variety of viral proteins, including adenovirus E1A (Yang et al., 1996) and E1B 55 kDa (Liu et al., 2000) , Epstein-Barr virus EBNA2 (Wang et al., 2000) , human cytomegalovirus IE86 (Bryant et al., 2000) , and now the HPV 6, 16 and 18 E7 proteins. The fact that these unrelated viral oncoproteins target pCAF during infection reflects the importance of this acetylase in cell regulation.
It was previously suggested that the interaction between E7 and pCAF might sequester the latter from NF-kB, as E7 modestly represses transcription of the NF-kB-responsive IL-8 gene. IL-8 is a potent chemoattractant for T-lymphocytes and neutrophils, and a reduction in its expression by E7 might contribute to the ability of the infected cell to evade the host immune response (Huang and McCance, 2002) . In addition, it has been shown that pCAF acetylates p53 in response to DNA damage, stimulating the latter's site-specific DNA-binding activity and leading to enhanced expression of genes that mediate cell cycle arrest, such as the cyclin-dependent kinase inhibitor p21 (Scolnick et al., 1997; Sakaguchi et al., 1998; Liu et al., 1999) . Importantly, E7 proteins from both high-and low-risk HPVs have been reported to inhibit p53-induced expression of p21 in at least some cell types Vaziri et al., 1997) . E7 proteins also inhibit chemical-and radiation-induced DNA-damage responses (Demers et al., 1996; Song et al., 1998) . These results suggest that the interaction of E7 with pCAF may contribute to the inhibition of p53 function observed in E7-expressing cells.
It is also possible that instead of, or in addition to disrupting the pCAF complex functions, E7 alters the enzymatic activities of the complex, as we have observed with recombinant pCAF in vitro (Figure 5 ), or directly targets it to new substrates, including other E7-binding proteins. This second possibility is potentially interesting since the functionally related adenovirus 5 E1A oncoprotein has been demonstrated to recruit the p300/ CBP acetyltransferase to acetylate pRb (Chan et al., 2001) . As summarized in Table 1 , pCAF may also play a role in transformation by E7, as the E7 L67R mutant, which does not bind pCAF in the yeast two-hybrid analyses (Figure 4c) , is impaired for the activation of E2F-dependent transcription and transformation in As previously reported . As previously reported (Brehm et al., 1999a) HPV E7 proteins interact with the pCAF N Avvakumov et al cooperation with ras , and is incapable of overcoming pRb-induced cell cycle arrest (Brehm et al., 1999a) . Interestingly, the adjacent S71I mutation, which retains binding to pCAF (Figure 4c ), does not impair transcriptional activation or transformation (Edmonds and Vousden, 1989; Phelps et al., 1992) and is still capable of overcoming pRb-induced cell cycle arrest (Brehm et al., 1999a) . Intriguingly, pCAF has also recently been implicated in calciumdependent differentiation of keratinocytes (Kawabata et al., 2001) , the cell type usually infected by HPVs. The effects of E7 on pCAF could therefore contribute to the loss of cell cycle control and differentiation observed in HPV-infected cells, functions common to the E7 proteins of both high-and low-risk HPVs. In conclusion, the interaction of E7 with pCAF likely provides another key mechanism by which HPV E7 can alter growth in the infected or transformed cell.
Materials and methods
Plasmids
The coding region for HPV 16 E7 WT was subcloned from pATH11-E7 (Carter et al., 1991) (Berger et al., 1992) expressing the VP16 transactivation domain fused to a Gal4 DBD was a gift from Dr. M.M. Smith (University of Virginia, Charlottesville, VA, USA). The gene encoding wild-type pRb (Dunaief et al., 1994) was a gift from Dr B. Strober (Columbia University, New York, NY, USA) and was subcloned into the yeast vector pEG202.
Yeast growth inhibition
Growth inhibition by E7 and VP16 was examined in yeast strains w3031a (MAta leu2-3,112 his3-11,15 trp1-1 ura3-1 ade2-1 can1-100) (provided by Dr M.M. Smith, University of Virginia, Charlottesville, VA, USA), FY86 (his3D200 leu2D1 ura3-53) and FY1370 (his3D200 leu2D1 ura3-53 gcn5::HIS3) (provided by Dr C. Brandl, University of Western Ontario, London, Ontario, Canada) (Roberts and Winston, 1997). Standard yeast culture media were prepared and yeast genetic manipulations were performed as previously described (Adams et al., 1998) . The effect of E7 and VP16 on yeast growth was documented by photography of colonies grown on selective plates for 3 days using a FOTO/Analyst Archiver Electronic documentation system (Fotodyne Inc., Hartland, WI, USA).
Yeast two-hybrid analysis
Yeast two-hybrid analyses were performed in strain EGY48 (MAta his3 trp1 ura3 6lexAop-LEU2) using the reporter plasmid pSH18-34 (Invitrogen, Carlsbad, CA, USA). Yeast were transformed with pEG202 expressing fragments of pRb or pCAF together with wild-type or mutant E7 in pJG4-5. Standard b-galactosidase assays were performed using chlorophenolred-b-D-galactopyranoside as substrate (Adams et al., 1998) .
Mammalian cell lines and luciferase assays
COS-1 and CV-1 African green monkey kidney cells were grown in Dulbecco's modified Eagle's medium (DMEM) with 10% fetal bovine serum. Transfections were carried out using Effectene transfection reagent (Qiagen Inc., Mississauga, Ontario, Canada) following manufacturer's instructions using a 1 : 10 total-DNA : Effectene ratio. Assays for luciferase activity were performed 24 h post-transfection following instructions provided by Promega Corporation (Madison, WI, USA).
Coprecipitation/GST pull-down analysis
Cells were harvested 48 h post-transfection from 100 mm dishes and lysed by incubation in 500 ml of lysis buffer (1% v/v NP-40, 25% v/v glycerol in PBS), containing Complete Protease Inhibitor Cocktail (Roche Diagnostics, Laval, Quebec, Canada) for 1 h on ice. GST-tagged E7 from 100 ml of clarified lysates was allowed to bind to 25 ml of glutathionesepharose beads for 1 h at 41C with constant gentle mixing. After four 500 ml washes with PBS, the beads were used either for HAT assays or for western blot analysis with the anti-GST antibody (Sigma-Aldrich Canada Ltd, Oakville, Ontario, Canada) or the 3F10 anti-HA antibody (Roche Diagnostics, Laval, Quebec, Canada).
HAT assays of GST pulldowns
A measure of 50 ml of glutathione-sepharose beads from the coprecipitation/GST pull-down (above) was mixed with 10 ml of IP-HAT buffer (50 mm Tris-HCl pH 8.0, 150 mm NaCl, 5 mm EDTA, 0.1% v/v NP-40) containing Complete Protease Inhibitor Cocktail (Roche Diagnostics, Laval, Quebec, Canada), 1.0 ml of acetyl-[ 3 H] CoA (ICN Biomedical Research Products, Costa Mesa, CA, USA) and 25 mg of histone II-A (Sigma-Aldrich Canada Ltd, Oakville, Ontario, Canada) or 25 mg of bovine serum albumin as a negative control. After 45 min at 301C, 20 ml of IP-HAT buffer was added to the beads, and samples were centrifuged at 21 000 g for 3 min at room temperature. A measure of 30 ml of each supernatant was spotted onto circles of p81 filter paper (Whatman Nuclepore Canada, Toronto, Ontario, Canada). The air-dried filters were soaked in sodium carbonate/bicarbonate solution (50 mm NaHCO 3 , 50 mm Na 2 CO 3 ) for 30 min at 371C, washed once in 30 ml of a 1 : 1 : 1 mixture of methanol:chloroform:acetone for 10 min and twice more for 5 min. The filters were air-dried and the amount of bound acetyl-[ 3 H] was measured by liquid scintillation counting.
HAT assays using recombinant proteins purified from bacteria GST-E7 WT , GST-E7 L67R , GST-E1A 13S and MBP-pCAF fusion proteins were expressed in and purified from the BL21 strain of E. coli as per protocols provided by affinity resin manufacturers (Amersham Pharmacia Biotech Inc., Baie d'Urfe´, Que´bec, Canada and New England Biolabs, Mississauga, Ontario, Canada) and dialyzed against MBP column buffer. They were then mixed at various ratios, and the mixture was evaluated for HAT activity following the protocol described above.
Transactivation by E7 WT and E7 L67R
CV-1 cells were cotransfected with the (gal) 6 -luc reporter plasmid containing a luciferase gene immediately downstream of six repeats of the GAL4p-binding region and a minimal TATA box together with pM, pM-E7 WT , pM-E7 DDLYC , pM-E7 L67R or pM-E7 S71I plasmids. At 24 h post-transfection cells were harvested and assayed for luciferase activity as described above.
